Abstract
BackgroundThe prognosis of patients with relapsed or progressive B cell (CD20+) non-Hodgkin’s lymphoma (B-NHL), including Burkitt lymphoma (BL), is dismal due to chemoradiotherapy resistance. Novel therapeutic strategies are urgently needed....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have